^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JRT39

    i
    Other names: JRT39
    Associations

    News

    Trials
    Company:
    Jalon Therap
    Drug class:
    AAC-11 protein inhibitor
    Associations

    News

    Trials
    almost3years
    AAC-11 survival pathways as therapeutic target in cancer: AAC-11 leucine-zipper domain derived peptides exert potent antitumor effects and exhibit favorable stability, pharmacokinetic and toxicology profiles (AACR 2023)
    Combined, our preclinical data confirm that interfering with AAC-11-related survival pathways is a promising novel anticancer strategy and support the development of JRT39 for the treatment of cancer.
    PK/PD data
    |
    PAK1 (p21 (RAC1) activated kinase 1)
    |
    JRT39